These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 27037627

  • 1. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
    Amoury M, Mladenov R, Nachreiner T, Pham AT, Hristodorov D, Di Fiore S, Helfrich W, Pardo A, Fey G, Schwenkert M, Thepen T, Kiessling F, Hussain AF, Fischer R, Kolberg K, Barth S.
    Int J Cancer; 2016 Aug 15; 139(4):916-27. PubMed ID: 27037627
    [Abstract] [Full Text] [Related]

  • 2. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M, Kolberg K, Pham AT, Hristodorov D, Mladenov R, Di Fiore S, Helfrich W, Kiessling F, Fischer R, Pardo A, Thepen T, Hussain AF, Nachreiner T, Barth S.
    Cancer Lett; 2016 Mar 28; 372(2):201-9. PubMed ID: 26806809
    [Abstract] [Full Text] [Related]

  • 3. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
    Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy JB, Brufsky A, Chivukula M, Khoury T, Hsu DS, Barry WT, Lyerly HK, Clay TM, Ferrone S.
    J Natl Cancer Inst; 2010 Oct 06; 102(19):1496-512. PubMed ID: 20852124
    [Abstract] [Full Text] [Related]

  • 4. Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand.
    Amoury M, Bauerschlag D, Zeppernick F, von Felbert V, Berges N, Di Fiore S, Mintert I, Bleilevens A, Maass N, Bräutigam K, Meinhold-Heerlein I, Stickeler E, Barth S, Fischer R, Hussain AF.
    Oncotarget; 2016 Aug 23; 7(34):54925-54936. PubMed ID: 27448975
    [Abstract] [Full Text] [Related]

  • 5. Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.
    Eng MS, Kaur J, Prasmickaite L, Engesæter BØ, Weyergang A, Skarpen E, Berg K, Rosenblum MG, Mælandsmo GM, Høgset A, Ferrone S, Selbo PK.
    Photochem Photobiol Sci; 2018 May 16; 17(5):539-551. PubMed ID: 29565434
    [Abstract] [Full Text] [Related]

  • 6. 212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models.
    Kasten BB, Oliver PG, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ.
    Int J Mol Sci; 2018 Mar 21; 19(4):. PubMed ID: 29561763
    [Abstract] [Full Text] [Related]

  • 7. CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate.
    Mungra N, Biteghe FAN, Malindi Z, Huysamen AM, Karaan M, Hardcastle NS, Bunjun R, Chetty S, Naran K, Lang D, Richter W, Hunter R, Barth S.
    J Cancer Res Clin Oncol; 2023 Oct 21; 149(13):12203-12225. PubMed ID: 37432459
    [Abstract] [Full Text] [Related]

  • 8. Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo.
    Hristodorov D, Nordlohne J, Mladenov R, Huhn M, Fischer R, Thepen T, Barth S.
    Br J Haematol; 2014 Jan 21; 164(2):251-7. PubMed ID: 24164493
    [Abstract] [Full Text] [Related]

  • 9. Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.
    Zhou H, Mohamedali KA, Gonzalez-Angulo AM, Cao Y, Migliorini M, Cheung LH, LoBello J, Lei X, Qi Y, Hittelman WN, Winkles JA, Tran NL, Rosenblum MG.
    Mol Cancer Ther; 2014 Nov 21; 13(11):2688-705. PubMed ID: 25239934
    [Abstract] [Full Text] [Related]

  • 10. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
    Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz LB, Roger P, Guiu S, Derocq D, Robin G, Michaud HA, Delpech H, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Simony-Lafontaine J, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget JP, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E.
    J Immunother Cancer; 2019 Feb 04; 7(1):29. PubMed ID: 30717773
    [Abstract] [Full Text] [Related]

  • 11. Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4.
    Wang X, Katayama A, Wang Y, Yu L, Favoino E, Sakakura K, Favole A, Tsuchikawa T, Silver S, Watkins SC, Kageshita T, Ferrone S.
    Cancer Res; 2011 Dec 15; 71(24):7410-22. PubMed ID: 22021902
    [Abstract] [Full Text] [Related]

  • 12. Selection of novel affinity-matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast display.
    Yu X, Qu L, Bigner DD, Chandramohan V.
    Protein Eng Des Sel; 2017 Sep 01; 30(9):639-647. PubMed ID: 28981720
    [Abstract] [Full Text] [Related]

  • 13. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS, Ho Y, Lin YW, Naveen Raj E, Liu KK, Chen C, Zhou XZ, Lu KP, Chao JI.
    Acta Biomater; 2019 Mar 01; 86():395-405. PubMed ID: 30660004
    [Abstract] [Full Text] [Related]

  • 14. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT, Unger GM, Abedin MJ, Vogel RI, Henzler CM, Ahmed K, Trembley JH.
    Breast Cancer Res; 2015 Mar 01; 17():19. PubMed ID: 25837326
    [Abstract] [Full Text] [Related]

  • 15. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ, Gong J, Hatch MM, Nguyen V, Hughes CC, Hutchins JT, Freimark BD.
    Breast Cancer Res; 2016 May 11; 18(1):50. PubMed ID: 27169467
    [Abstract] [Full Text] [Related]

  • 16. Synthetic human monoclonal antibody targets hIL1 receptor accessory protein chain with therapeutic potential in triple-negative breast cancer.
    Zheng P, Zhang Y, Zhang B, Wang Y, Wang Y, Yang L.
    Biomed Pharmacother; 2018 Nov 11; 107():1064-1073. PubMed ID: 30257318
    [Abstract] [Full Text] [Related]

  • 17. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma.
    Rivera Z, Ferrone S, Wang X, Jube S, Yang H, Pass HI, Kanodia S, Gaudino G, Carbone M.
    Clin Cancer Res; 2012 Oct 01; 18(19):5352-63. PubMed ID: 22893632
    [Abstract] [Full Text] [Related]

  • 18. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
    Vinet M, Suresh S, Maire V, Monchecourt C, Némati F, Lesage L, Pierre F, Ye M, Lescure A, Brisson A, Meseure D, Nicolas A, Rigaill G, Marangoni E, Del Nery E, Roman-Roman S, Dubois T.
    Cancer Med; 2019 May 01; 8(5):2414-2428. PubMed ID: 30957988
    [Abstract] [Full Text] [Related]

  • 19. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
    Chen B, Wang J, Dai D, Zhou Q, Guo X, Tian Z, Huang X, Yang L, Tang H, Xie X.
    J Exp Clin Cancer Res; 2017 May 12; 36(1):65. PubMed ID: 28494797
    [Abstract] [Full Text] [Related]

  • 20. Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells.
    Cooney CA, Jousheghany F, Yao-Borengasser A, Phanavanh B, Gomes T, Kieber-Emmons AM, Siegel ER, Suva LJ, Ferrone S, Kieber-Emmons T, Monzavi-Karbassi B.
    Breast Cancer Res; 2011 Jun 09; 13(3):R58. PubMed ID: 21658254
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.